Literature DB >> 11448918

Circulating hepatitis B virus nucleic acids in chronic infection : representation of differently polyadenylated viral transcripts during progression to nonreplicative stages.

Q Su1, S F Wang, T E Chang, R Breitkreutz, H Hennig, K Takegoshi, L Edler, C H Schröder.   

Abstract

PURPOSE: Beside the established maturation of hepatitis B virus (HBV) transcripts at a polyadenylation signal downstream of the HBV x protein open reading frame, maturation at an internal polyadenylation signal has been observed in the chronically infected liver. In the present study, it was the aim to identify the respective circulating full-length and truncated transcripts in plasma/serum of carriers. EXPERIMENTAL
DESIGN: Nucleic acids extracted from sera were analyzed using established PCR and reverse transcription-PCR procedures targeted to HBV x protein gene regions. Amplification products were cloned and sequenced.
RESULTS: Base substitution patterns were determined, which indicated infection stages advanced to different degrees regardless of the transcript type analyzed. HBV full-length RNA (fRNA) showed a high correlation with hepatitis B e antigen and viral DNA, indicative for a replicative infection. In contrast, truncated RNA (trRNA) appeared to be independent of hepatitis B e antigen and showed only a weak association with circulating viral DNA. No correlation was observed between the levels of trRNA and the apparent liver damage as reflected by alanine transaminase levels. An age-dependent representation of fRNA and trRNA was observed: fRNA decreased progressively to low levels, whereas trRNA remained at comparably high values. trRNA and RNA not polyadenylated at either of the two polyadenylation signals were detected even in the absence of any other conventional HBV seromarker, including viral DNA. This was shown for patients with cryptogenic cirrhosis and hepatitis C virus carriers.
CONCLUSIONS: The identification of HBV RNA in human serum has a diagnostic potential for apparent and for inapparent infection stages.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11448918

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  21 in total

1.  RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg.

Authors:  Christine I Wooddell; Man-Fung Yuen; Henry Lik-Yuen Chan; Robert G Gish; Stephen A Locarnini; Deborah Chavez; Carlo Ferrari; Bruce D Given; James Hamilton; Steven B Kanner; Ching-Lung Lai; Johnson Y N Lau; Thomas Schluep; Zhao Xu; Robert E Lanford; David L Lewis
Journal:  Sci Transl Med       Date:  2017-09-27       Impact factor: 17.956

2.  Serum HBV RNA as a possible marker of HBV replication in the liver during nucleot(s)ide analogue therapy.

Authors:  Masayuki Kurosaki; Kaoru Tsuchiya; Hiroyuki Nakanishi; Jun Itakura; Namiki Izumi
Journal:  J Gastroenterol       Date:  2013-03-30       Impact factor: 7.527

3.  Mapping of histone modifications in episomal HBV cccDNA uncovers an unusual chromatin organization amenable to epigenetic manipulation.

Authors:  Philipp Tropberger; Alexandre Mercier; Margaret Robinson; Weidong Zhong; Don E Ganem; Meghan Holdorf
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-05       Impact factor: 11.205

4.  Hepatitis B virus RNA is measurable in serum and can be a new marker for monitoring lamivudine therapy.

Authors:  Akinori Rokuhara; Akihiro Matsumoto; Eiji Tanaka; Takeji Umemura; Kaname Yoshizawa; Tatsuji Kimura; Noboru Maki; Kendo Kiyosawa
Journal:  J Gastroenterol       Date:  2006-08       Impact factor: 7.527

5.  Serum Hepatitis B Virus DNA, RNA, and HBsAg: Which Correlated Better with Intrahepatic Covalently Closed Circular DNA before and after Nucleos(t)ide Analogue Treatment?

Authors:  Yuhua Gao; Yutang Li; Qinghua Meng; Zhanqing Zhang; Ping Zhao; Qinghua Shang; Yue Li; Mingze Su; Tong Li; Xueen Liu; Hui Zhuang
Journal:  J Clin Microbiol       Date:  2017-07-26       Impact factor: 5.948

Review 6.  Use of Current and New Endpoints in the Evaluation of Experimental Hepatitis B Therapeutics.

Authors:  Timothy M Block; Stephen Locarnini; Brian J McMahon; Barbara Rehermann; Marion G Peters
Journal:  Clin Infect Dis       Date:  2017-05-01       Impact factor: 9.079

7.  Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients.

Authors:  Masataka Tsuge; Eisuke Murakami; Michio Imamura; Hiromi Abe; Daiki Miki; Nobuhiko Hiraga; Shoichi Takahashi; Hidenori Ochi; C Nelson Hayes; Hiroyuki Ginba; Kazuhiro Matsuyama; Hiroiku Kawakami; Kazuaki Chayama
Journal:  J Gastroenterol       Date:  2013-02-09       Impact factor: 7.527

Review 8.  Serum Hepatitis B Virus RNA: A New Potential Biomarker for Chronic Hepatitis B Virus Infection.

Authors:  Shi Liu; Bin Zhou; Juan D Valdes; Jian Sun; Haitao Guo
Journal:  Hepatology       Date:  2019-03-20       Impact factor: 17.425

9.  Effects of entecavir on hepatitis B virus covalently closed circular DNA in hepatitis B e antigen-positive patients with hepatitis B.

Authors:  Ming Shi; Wan-Li Sun; Yan-Yan Hua; Bo Han; Long Shi
Journal:  PLoS One       Date:  2015-02-03       Impact factor: 3.240

10.  Targeted Long-Read Sequencing Reveals Comprehensive Architecture, Burden, and Transcriptional Signatures from Hepatitis B Virus-Associated Integrations and Translocations in Hepatocellular Carcinoma Cell Lines.

Authors:  Ricardo Ramirez; Nicholas van Buuren; Lindsay Gamelin; Cameron Soulette; Lindsey May; Dong Han; Mei Yu; Regina Choy; Guofeng Cheng; Neeru Bhardwaj; Joy Chiu; Robert C Muench; William E Delaney; Hongmei Mo; Becket Feierbach; Li Li
Journal:  J Virol       Date:  2021-07-21       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.